(Posted By: Josi Creek)
JANUARY 12, 2010, 10:26 A.M. ET
DOW JONES NEWSWIRES
Biogen Idec Inc. (BIIB) said sales of its controversial multiple sclerosis treatment Tysabri surpassed $1 billion in 2009, reaching blockbuster status, as the number of patients using the treatment climbed 30%.
The company estimates that at the end of December, the number of patients using Tysabri was 48,800 globally; including 24,500 in the U.S., 23,700 in the rest of the world and 600 in clinical trials.
The company faces continued pressure from activist shareholders and concerns about the growth trajectory of the controversial multiple sclerosis treatment, sold with Elan Corp. (ELN).
To read the full story, click here.
